The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and Viking Therapeutics ... deserves kudos for being so bold in its marketing approach. I'm not convinced any ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking ... Hims & Hers deserves kudos for being so bold in its marketing approach. I'm not convinced any positive ...

WEIGHT loss jabs slash alcohol cravings and can curb dangerous binge drinking, new research suggests.  The active drug ...